[go: up one dir, main page]

PE20151907A1 - Compuestos y usos de estos para la modulacion de la hemoglobina - Google Patents

Compuestos y usos de estos para la modulacion de la hemoglobina

Info

Publication number
PE20151907A1
PE20151907A1 PE2015001920A PE2015001920A PE20151907A1 PE 20151907 A1 PE20151907 A1 PE 20151907A1 PE 2015001920 A PE2015001920 A PE 2015001920A PE 2015001920 A PE2015001920 A PE 2015001920A PE 20151907 A1 PE20151907 A1 PE 20151907A1
Authority
PE
Peru
Prior art keywords
hemoglobin
compounds
ring
modulation
methods
Prior art date
Application number
PE2015001920A
Other languages
English (en)
Inventor
Jason R Harris
Ii Stephen L Gwalteney
Qing Xu
Zhe Li
Calvin W Yee
Brian W Metcalf
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51580734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151907(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US13/815,776 external-priority patent/US9458139B2/en
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of PE20151907A1 publication Critical patent/PE20151907A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de Formula A, en donde el anillo A es un heteroarilo de 5-10 miembros opcionalmente sustituido; el anillo B es un arilo C6-C10 o heterociclo de 4-10 miembros; Y y Z son O, S, SO, entre otros; y V1 y V2 son alcoxi C1-C6 o juntos forman un anillo. Estos compuestos, asi como las composiciones farmaceuticas que los contienen, son adecuados como moduladores de la hemoglobina. Se incluyen metodos e intermedios para su preparacion, y metodos para su uso en el tratamiento de trastornos mediados por la hemoglobina y trastornos que se podrian beneficiar de la oxigenacion celular y/o tisular
PE2015001920A 2013-03-15 2014-03-10 Compuestos y usos de estos para la modulacion de la hemoglobina PE20151907A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/815,776 US9458139B2 (en) 2013-03-15 2013-03-15 Compounds and uses thereof for the modulation of hemoglobin
US201361905802P 2013-11-18 2013-11-18

Publications (1)

Publication Number Publication Date
PE20151907A1 true PE20151907A1 (es) 2016-01-20

Family

ID=51580734

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001920A PE20151907A1 (es) 2013-03-15 2014-03-10 Compuestos y usos de estos para la modulacion de la hemoglobina

Country Status (18)

Country Link
EP (1) EP2970315B1 (es)
JP (2) JP6401772B2 (es)
KR (1) KR20150132147A (es)
CN (1) CN105209469A (es)
AP (1) AP2015008720A0 (es)
AU (1) AU2014237361A1 (es)
BR (1) BR112015021980A2 (es)
CA (1) CA2902721C (es)
EA (1) EA201591427A1 (es)
ES (1) ES2909634T3 (es)
IL (1) IL240845A0 (es)
MX (1) MX388013B (es)
PE (1) PE20151907A1 (es)
SG (1) SG11201507351PA (es)
TW (1) TW201518286A (es)
UY (1) UY35425A (es)
WO (1) WO2014150289A1 (es)
ZA (1) ZA201506390B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2014007805A0 (en) 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
WO2013102145A1 (en) 2011-12-28 2013-07-04 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
AP2015008718A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
ES2852054T3 (es) 2013-03-15 2021-09-10 Global Blood Therapeutics Inc Compuestos y usos de los mismos para la modulación de hemoglobina
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
MY180206A (en) 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SG10201911668VA (en) 2014-02-07 2020-01-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3257291C (en) 2015-10-16 2026-01-06 Abbvie Inc. Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
HUE072191T2 (hu) 2015-12-04 2025-10-28 Global Blood Therapeutics Inc A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje
TWI663160B (zh) 2016-05-12 2019-06-21 全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
EP3472150A1 (en) 2016-06-17 2019-04-24 Fronthera U.S. Pharmaceuticals LLC Hemoglobin modifier compounds and uses thereof
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
CN113316568B (zh) * 2018-11-19 2024-11-08 全球血液疗法股份有限公司 能够调节血红蛋白的2-甲酰基-3-羟基苯基氧基甲基化合物
CA3121139A1 (en) 2018-11-29 2020-06-04 Pfizer Inc. Pyrazoles as modulators of hemoglobin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2090830B (en) * 1980-12-18 1984-09-26 Wellcome Found Formyl ether derivatives
FR2680512B1 (fr) * 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO1994022857A1 (fr) * 1993-04-07 1994-10-13 Taiho Pharmaceutical Co., Ltd. Derive de thiazolidine et composition pharmaceutique contenant ce derive
AU2995497A (en) * 1996-07-26 1997-11-19 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
US6184228B1 (en) * 1999-05-25 2001-02-06 Anadys Pharmaceuticals, Inc. Anti-sickling agents: selection methods and effective compounds
AUPQ105499A0 (en) * 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
US20030022923A1 (en) * 2001-03-01 2003-01-30 Medinox, Inc. Methods for treatment of sickle cell anemia
EP1567490B1 (en) * 2002-12-04 2011-10-05 Virginia Commonwealth University Anti-sickling agents
JP5089170B2 (ja) * 2003-12-02 2012-12-05 セルジーン コーポレイション 異常ヘモグロビン症及び貧血症の治療及び管理のための方法及び組成物
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
TW201139406A (en) * 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
US20120122928A1 (en) * 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
AP2014007805A0 (en) * 2011-12-28 2014-07-31 Cytokinetics Inc The Regents Of The University Of California Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation
MY180206A (en) * 2013-03-15 2020-11-25 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin

Also Published As

Publication number Publication date
JP6401772B2 (ja) 2018-10-10
CA2902721A1 (en) 2014-09-25
EP2970315B1 (en) 2021-09-15
KR20150132147A (ko) 2015-11-25
CN105209469A (zh) 2015-12-30
JP2016512824A (ja) 2016-05-09
EA201591427A1 (ru) 2016-01-29
CA2902721C (en) 2021-09-14
EP2970315A4 (en) 2016-08-17
EP2970315A1 (en) 2016-01-20
WO2014150289A1 (en) 2014-09-25
BR112015021980A2 (pt) 2017-07-18
MX388013B (es) 2025-03-19
TW201518286A (zh) 2015-05-16
MX2015011509A (es) 2016-05-31
ZA201506390B (en) 2017-03-29
UY35425A (es) 2014-10-31
IL240845A0 (en) 2015-10-29
ES2909634T3 (es) 2022-05-09
AU2014237361A1 (en) 2015-09-17
SG11201507351PA (en) 2015-10-29
JP2018188481A (ja) 2018-11-29
AP2015008720A0 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
PE20151907A1 (es) Compuestos y usos de estos para la modulacion de la hemoglobina
MX378131B (es) Compuestos y sus usos para modular la hemoglobina.
CL2015002501A1 (es) Compuestos y usos de estos para la modulación de la hemoglobina
AR095341A1 (es) Compuestos y usos para la modulación de hemoglobina
CL2015002567A1 (es) Compuestos y sus usos para modular la hemoglobina
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
AR096052A1 (es) Compuestos y sus usos para la modulación de hemoglobina
AR095340A1 (es) Compuestos y sus usos para la modulación de hemoglobina
UY35827A (es) Derivados de triazolopirazina como inhibidores de la proteína brd4
PE20151280A1 (es) Compuestos y metodos para la modulacion de quinasas y sus indicaciones
CO7101245A2 (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido
UY35639A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI201400081A (es) Nuevos derivados de indolizina , su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
MX373141B (es) Anticuerpos anti-homologo relacionado con las convulsiones 6 (anti-sez6) y metodos de uso.
AR095342A1 (es) Piridinas 2,3-sustituidas y su uso para la modulación de hemoglobina
ECSP14013215A (es) Compuestos novedosos
CR20150549A (es) Compuestos heterocíclicos y sus usos
PE20181345A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer
MX2013002255A (es) Moduladores de proteina de notum y metodos de uso.
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
EA201270808A1 (ru) Новые формы рифаксимина и их применение
NI201600015A (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CO6410315A2 (es) Nuevos anticuerpos anti-alfa5beta1 y sus usos

Legal Events

Date Code Title Description
FD Application declared void or lapsed